HC Wainwright reiterates Buy on Edgewise Therapeutics; $57 target
HC Wainwright & Co. maintained a Buy rating on Edgewise Therapeutics and kept a $57.00 price target.
Story updates
10:53:23 AM UTC
SquawkNews
Ratings actions
HC Wainwright & Co. maintained a Buy rating on Edgewise Therapeutics and kept a $57.00 price target.